Cns Pharmaceuticals, INC S-1 registration statements

CNS Pharmaceuticals launches an offering of common stock and warrants aiming to raise up to $7 million for working capital and general corporate purposes.

CNS Pharmaceuticals plans to offer shares of common stock, pre-funded warrants, and Series F warrants in a best-efforts offering.

CNS Pharmaceuticals is undertaking a public offering to raise capital for its CNS-201 trial, other research and development, and working capital.

CNS Pharmaceuticals has filed a registration statement for the resale of up to 2,359,000 shares of its common stock issuable upon the exercise of outstanding warrants held by selling shareholders.

CNS Pharmaceuticals is launching a securities offering to raise up to $30 million, primarily to fund its CNS-201 trial for Glioblastoma.

CNS Pharmaceuticals is launching a public offering of common stock, pre-funded warrants, and common warrants to fund its clinical trial and for general corporate purposes.